NCT00367965

Study of Eszopiclone Compared to Placebo on Daytime Function in Subjects With Insomnia Related to Rheumatoid Arthritis

The Effect of Eszopiclone 3 mg Compared to Placebo on Daytime Function in Subjects With Insomnia Related to Rheumatoid Arthritis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 153 (actual)
• Sponsor: Sumitomo Pharma America, Inc. · Industry
• Sex: All
• Age: 25 Years – 64 Years
• Healthy volunteers: Not accepted

Summary

To demonstrate subjective sleep efficacy of eszopiclone 3 mg in subjects with insomnia related to rheumatoid arthritis (RA).

Detailed description

A multicenter, randomized, double-blind, placebo controlled, parallel group study of eszopiclone 3 mg in subjects with insomnia related to rheumatoid arthritis. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

Conditions

• Insomnia
• Arthritis, Rheumatoid

Interventions

Type	Name	Description
DRUG	Eszopiclone	eszopiclone 3 mg
DRUG	placebo	placebo tablet

Timeline

• Start date: 2004-02-01
• Primary completion: 2004-11-01
• Completion: 2004-11-01
• First posted: 2006-08-24
• Last updated: 2012-02-22

Locations

38 sites across 1 country: United States